XERS

XERS R&D Expense Growth

21.93%Fiscal year

Period ending:

XERS FY R&D Growth (YoY)%
XERS FY R&D Growth (YoY)121.63%-85.42%
2016-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year. Growth compares with the corresponding period one year earlier.

XERS r&d expense growth history

Year-over-year research & development expense growth. The available annual fiscal periods series contains 10 observations from Dec 31, 2016 to Dec 31, 2025.

Xeris Biopharma Holdings Inc R&D Expense Growth — Annual fiscal periods
Period endingR&D Expense Growth
21.9288%
14.4085%
6.5582%
-16.6693%
20.2619%
-65.3844%
48.6643%
101.5967%
96.9721%
0%

Compare r&d expense growth

All XERS financial metrics · XERS stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.